Since myeloid cells are increasingly recognized as key effectors for both antibody and CAR-T mechanisms of action in solid cancers, future studies will need to characterize the effector phenotype of the infiltrating myeloid cells in ATRX-mutated neuroblastoma. The gene discussed is ATRX; the disease is neuroblastoma.